EXACT Sciences (NASDAQ:EXAS) Upgraded at Zacks Investment Research
According to Zacks, “EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated. “
Several other research firms have also recently weighed in on EXAS. BidaskClub raised Misonix from a buy rating to a strong-buy rating in a research report on Wednesday, July 3rd. UBS Group cut Advanced Disposal Services from a buy rating to a neutral rating and set a $33.00 price objective on the stock. in a research report on Wednesday, May 1st. They noted that the move was a valuation call. Canaccord Genuity boosted their price target on TELUS from C$51.00 to C$52.00 in a research report on Wednesday, May 1st. Craig Hallum boosted their price target on 1-800-Flowers.Com from $26.00 to $20.00 and gave the stock a buy rating in a research report on Wednesday, May 1st. Finally, BTIG Research boosted their price target on Apple to $234.00 and gave the stock a buy rating in a research report on Wednesday, May 1st. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. EXACT Sciences has a consensus rating of Buy and a consensus price target of $108.45.
EXACT Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Tuesday, April 30th. The medical research company reported ($0.66) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by ($0.01). The firm had revenue of $162.00 million for the quarter, compared to the consensus estimate of $153.07 million. EXACT Sciences had a negative net margin of 41.58% and a negative return on equity of 28.83%. The business’s revenue was up 79.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.33) earnings per share. As a group, equities analysts forecast that EXACT Sciences will post -2.18 EPS for the current year.
Several institutional investors and hedge funds have recently modified their holdings of the company. Allstate Corp boosted its position in shares of EXACT Sciences by 1.4% in the 1st quarter. Allstate Corp now owns 7,080 shares of the medical research company’s stock worth $613,000 after purchasing an additional 97 shares in the last quarter. GABELLI & Co INVESTMENT ADVISERS INC. raised its holdings in EXACT Sciences by 2.4% in the 1st quarter. GABELLI & Co INVESTMENT ADVISERS INC. now owns 4,250 shares of the medical research company’s stock worth $368,000 after acquiring an additional 100 shares during the last quarter. Gofen & Glossberg LLC IL raised its holdings in EXACT Sciences by 1.8% in the 1st quarter. Gofen & Glossberg LLC IL now owns 8,375 shares of the medical research company’s stock worth $725,000 after acquiring an additional 150 shares during the last quarter. First Hawaiian Bank raised its holdings in EXACT Sciences by 160.0% in the 1st quarter. First Hawaiian Bank now owns 325 shares of the medical research company’s stock worth $28,000 after acquiring an additional 200 shares during the last quarter. Finally, CWM LLC raised its holdings in EXACT Sciences by 35.3% in the 1st quarter. CWM LLC now owns 831 shares of the medical research company’s stock worth $72,000 after acquiring an additional 217 shares during the last quarter. 86.27% of the stock is currently owned by hedge funds and other institutional investors.
About EXACT Sciences
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.
Recommended Story: What is the Dow Jones Industrial Average (DJIA)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.